



Genomic Health, Inc.  
Investor Relations Department  
301 Penobscot Dr.  
Redwood City, CA 94063  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: GHDX

Last Trade:	35.05
Trade Time:	10:36 AM ET Jan 23, 2018
Change:	0.10  (+0.286%)
Day Range	34.46 - 35.22
52-Week Range	26.37 - 37.50
Volume	11,965


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

**Genomic Health, Inc.** (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Dec 21, 2017*  
[Genomic Health to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)
- Dec 11, 2017*  
[Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum](#)
- Dec 6, 2017*  
[Genomic Health Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Oncotype DX® Genomic Prostate Score™ Test for Potential Drug Development](#)
- Nov 30, 2017*  
[Genomic Health Announces Presentation of 10 Oncotype DX® Studies at the 2017 San Antonio Breast Cancer Symposium Demonstrating Test's Unique Value in Predicting Neoadjuvant Treatment Benefit and Guiding Breast Cancer Staging](#)
- Nov 28, 2017*  
[Genomic Health and Cleveland Diagnostics Announce Strategic Collaboration to Develop and Commercialize New Prostate Cancer Tests](#)

## Financials & Filings [\[ View all \]](#)

- Mar 15, 2017*  
[Annual Report \(10-K\)](#)
- Apr 28, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 9, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 10, 2017*  
[Quarterly Report \(10-Q\)](#)

